A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory acute lymphoblastic leukemia (ITCC-059)
A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory acute lymphoblastic leukemia (ITCC-059)
This trial examines the safety and tolerability of inotuzumab. Patients with relapsed or refractory CD22 positive B-precursor leukemia (stratum A) or other CD22-positive B-cell cancers (stratum B) can be included in this trial.
Erasmus Medical Center,
Niederlande